Browsing Tag
VB0004
3 posts
Vectus Biosystems gains FDA pre-IND meeting for VB0004 pulmonary fibrosis drug candidate
Vectus Biosystems Limited has secured an FDA pre-IND meeting for VB0004 in idiopathic pulmonary fibrosis, advancing its lead antifibrotic programme toward a possible US clinical-development pathway.
Vectus Biosystems (ASX:VBS) appoints Cardinal Health Regulatory Sciences for VB0004 FDA pathway
Vectus Biosystems has formalised its United States regulatory strategy for VB0004, but financing, clinical execution and evidence of human antifibrotic activity remain the decisive valuation tests.
Vectus Biosystems (ASX:VBS) exits VB4-P5—can this microcap regain momentum with VB0004?
Vectus Biosystems signs US$3M deal to license VB4-P5 to XORTX. Can its lead fibrosis drug VB0004 now deliver the next big upside?